LL-37

LL-37 is the sole cathelicidin-derived antimicrobial peptide produced by humans, representing a cornerstone of our innate immune defense. The name derives from its structure: 37 amino acids beginning with two leucine (L) residues. This peptide is cleaved from its precursor protein, human cationic antimicrobial protein 18 (hCAP18), by proteinase 3 in neutrophils or by other proteases in epithelial tissues.

Unlike conventional antibiotics that target specific molecular pathways, LL-37 kills pathogens through direct physical disruption of their membranes while simultaneously orchestrating broader immune responses. This dual functionality—combining antimicrobial killing with immunomodulation—makes LL-37 fundamentally different from any pharmaceutical antibiotic.

The peptide is expressed throughout the body wherever infection risk exists: skin and epithelial surfaces, the respiratory tract, gastrointestinal mucosa, and the urogenital system. Neutrophils, the first-responder immune cells, carry substantial LL-37 stores in their specific granules, releasing it at sites of infection. When skin is wounded or tissues become infected, local LL-37 production increases dramatically.

Interest in LL-37 has surged as antibiotic resistance has become a global health crisis. The World Health Organization lists antimicrobial resistance among the top ten threats to global health, and LL-37 represents a fundamentally different approach to infection control—one that bacteria find much harder to evade.

LL-37's mechanisms of action span direct antimicrobial killing, immune modulation, and tissue repair—a versatility that reflects its central role in host defense.

Membrane Disruption: The Primary Kill Mechanism

LL-37 adopts an amphipathic alpha-helical structure in membrane environments, with hydrophobic residues on one face and positively charged residues on the other. This structure allows the peptide to selectively target bacterial membranes, which have higher negative surface charge than human cell membranes.

The speed of this mechanism is remarkable—bacterial killing can occur within minutes of exposure. This rapid action, combined with the physical nature of membrane disruption, makes resistance development extremely difficult.

Endotoxin Neutralization

When gram-negative bacteria die, they release lipopolysaccharide (LPS), also known as endotoxin, which can trigger severe inflammatory responses including septic shock. LL-37 binds directly to LPS, neutralizing its inflammatory potential. This dual action—killing bacteria while neutralizing their toxins—provides comprehensive protection against gram-negative infections.

Biofilm Disruption

Biofilms are structured bacterial communities encased in a protective matrix, making them up to 1,000 times more resistant to antibiotics than free-floating bacteria. LL-37 disrupts biofilm formation and can penetrate established biofilms, making it valuable against chronic infections where biofilms are prevalent—from wound infections to implant-associated infections to chronic sinusitis.

Immunomodulatory Functions

Beyond direct killing, LL-37 shapes immune responses through multiple mechanisms:

• Chemotaxis: Attracts immune cells (neutrophils, monocytes, T cells) to infection sites
• Cytokine modulation: Influences production of inflammatory and anti-inflammatory cytokines
• Dendritic cell activation: Bridges innate and adaptive immunity by activating antigen-presenting cells
• Macrophage polarization: Promotes pro-resolving macrophage phenotypes to facilitate healing

Wound Healing Promotion

LL-37 actively promotes tissue repair through several mechanisms:

LL-37 research spans three decades, with particular acceleration in recent years as the antibiotic resistance crisis has intensified. The following summarizes key findings across major research areas:

Antimicrobial Efficacy

Laboratory studies demonstrate LL-37's broad-spectrum activity against gram-positive bacteria (including MRSA and VRE), gram-negative bacteria (including Pseudomonas aeruginosa and E. coli), fungi (Candida species), and enveloped viruses (including influenza and herpes simplex). Minimum inhibitory concentrations (MICs) typically range from 1-64 μg/mL depending on the pathogen and test conditions.

Biofilm Research

Research published in Clinical Infectious Diseases (2008) demonstrated LL-37's ability to prevent Pseudomonas aeruginosa biofilm formation at sub-MIC concentrations and to promote the dispersal of pre-formed biofilms. This is particularly significant given that biofilm-associated infections account for approximately 80% of all chronic bacterial infections.

Wound Healing Studies

Animal studies have consistently shown accelerated wound healing with LL-37 application. A key study in the British Journal of Dermatology demonstrated that LL-37-deficient mice showed impaired wound healing, while topical LL-37 application accelerated healing in wild-type animals. The peptide increased wound re-epithelialization rates and improved tissue organization.

Synergy with Antibiotics

Multiple studies have demonstrated synergistic effects when LL-37 is combined with conventional antibiotics. Research shows enhanced killing of MRSA when LL-37 is combined with oxacillin, and improved efficacy against gram-negative bacteria when combined with various antibiotic classes. These combinations often achieve the same killing at lower antibiotic concentrations, potentially reducing resistance selection pressure.

Clinical Trials

LL-37 and its derivatives have entered clinical trials for several indications:

• Chronic leg ulcers: Phase I/II trials of topical LL-37 showed promising safety and preliminary efficacy signals
• Melanoma: Intratumoral LL-37 injection combined with CpG oligonucleotides has been investigated as an immunotherapy approach
• OP-145 (LL-37 derivative): Evaluated for chronic middle ear infections with favorable safety profile

Vitamin D Relationship

A substantial body of research published in Future Microbiology and other journals has established the vitamin D-LL-37 axis. Studies show that vitamin D supplementation increases LL-37 expression in respiratory epithelial cells, monocytes, and keratinocytes. This relationship has implications for understanding infection susceptibility in vitamin D-deficient populations and suggests that ensuring adequate vitamin D status may be a practical way to support endogenous LL-37 production.

As LL-37 remains investigational for therapeutic applications, established clinical dosing protocols do not exist. The following summarizes approaches used in research settings—not recommendations for human use.

Research Concentrations

In vitro antimicrobial studies typically use LL-37 at concentrations of 1-100 μg/mL. Effective antimicrobial concentrations vary by pathogen:

Administration Routes Under Investigation

Topical: The most studied route for wound healing applications. LL-37 can be formulated in gels, creams, or wound dressings. Topical delivery localizes the peptide where needed while minimizing systemic exposure.

Injection: Local injection has been explored for deep tissue infections and in cancer immunotherapy studies. Intratumoral injection of LL-37 combined with immune adjuvants has been evaluated in melanoma trials.

Inhalation: Being investigated for respiratory infections, particularly for conditions like cystic fibrosis where chronic Pseudomonas infection is common.

Stability and Handling

LL-37 is supplied as a lyophilized powder for research use. Standard handling practices:

Modified Peptides

Researchers have developed LL-37 derivatives to overcome the native peptide's limitations. Modifications include:

• Truncated versions: Shorter peptides retaining antimicrobial activity (e.g., LL-23, LL-17)
• D-amino acid substitutions: Increased protease resistance
• Lipidation: Improved membrane interaction and activity
• Cyclization: Enhanced stability and sometimes improved activity

LL-37's status as an endogenous human peptide provides inherent biocompatibility advantages. However, therapeutic applications require careful consideration of dose-dependent effects and context-specific responses.

Preclinical Safety Data

Topical LL-37 application in animal wound healing studies has generally shown good local tolerability. Systemic exposure at research doses has not revealed major toxicity in animal models. The peptide's short half-life limits systemic accumulation.

Immunological Considerations

LL-37's immunomodulatory properties are context-dependent:

• Pro-inflammatory potential: In some settings, LL-37 can enhance inflammatory responses. In diseases like psoriasis and rosacea, elevated LL-37 contributes to pathological inflammation.
• Anti-inflammatory effects: In other contexts, LL-37 dampens inflammation by neutralizing LPS and modulating cytokine production.
• Autoimmune considerations: LL-37 has been implicated in forming complexes with self-DNA that can trigger type I interferon responses, potentially relevant to conditions like lupus.

Clinical Trial Safety

Phase I/II clinical trials of topical LL-37 for chronic leg ulcers reported:

• Good local tolerability
• No serious adverse events attributed to treatment
• Mild, transient local reactions in some patients (redness, warmth) consistent with expected immunomodulatory activity

Selectivity for Bacterial Membranes

LL-37's selectivity for bacterial over human membranes provides a therapeutic window, but this selectivity is not absolute. Factors contributing to preferential bacterial killing include:

• Higher negative charge on bacterial membranes (phosphatidylglycerol, cardiolipin) vs. zwitterionic phospholipids in human membranes
• Cholesterol content in human membranes reduces LL-37 insertion
• Differences in membrane fluidity and lipid composition

However, at sufficiently high concentrations, these differences become less protective, and human cell damage can occur.